Nuclear Receptor & In Vitro Toxicology Solutions™

Get all the latest news from INDIGO

  • This field is for validation purposes and should be left unchanged.
  • HOME
  • ABOUT
    • About
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
  • PRODUCTS
    • Assays
    • Ortholog Assays
    • Growth Factor Receptors
    • In Vitro Toxicology Platform
    • MDR1 / Human P-Glycoprotein
    • Gene Expression
    • NASH Nuclear Receptors For Research
    • Disease States
    • Live Cell Multiplex
    • Custom Assay Development
  • TECHNICAL
    • Nuclear Receptor Profiling & Panels
    • Assay Kit Platform & Formats
    • FAQ
    • Discovery Toxicology
    • upcyte® Hepatocytes
    • Technical Manuals & Product Listing
    • Safety Data Sheets
    • Product Policies
    • Terms & Conditions
    • Limited Use Disclosures
  • CONTACT US
    • Contact INDIGO
    • Request Information
    • Request a Quote
    • Employment
    • Distributors
  • RESOURCES
    • Blog
    • Nuclear Receptor Resource
    • Scientific Whitepapers from INDIGO
    • New Research Publications
    • Scientific Posters
    • INDIGO Press Releases
    • INDIGO in the News

Nuclear Receptor & In Vitro Toxicology Solutions™

Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • HOME
  • ABOUT
    • About
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
  • PRODUCTS
    • Assays
    • Ortholog Assays
    • Growth Factor Receptors
    • In Vitro Toxicology Platform
    • MDR1 / Human P-Glycoprotein
    • Gene Expression
    • NASH Nuclear Receptors For Research
    • Disease States
    • Live Cell Multiplex
    • Custom Assay Development
  • TECHNICAL
    • Nuclear Receptor Profiling & Panels
    • Assay Kit Platform & Formats
    • FAQ
    • Discovery Toxicology
    • upcyte® Hepatocytes
    • Technical Manuals & Product Listing
    • Safety Data Sheets
    • Product Policies
    • Terms & Conditions
    • Limited Use Disclosures
  • CONTACT US
    • Contact INDIGO
    • Request Information
    • Request a Quote
    • Employment
    • Distributors
  • RESOURCES
    • Blog
    • Nuclear Receptor Resource
    • Scientific Whitepapers from INDIGO
    • New Research Publications
    • Scientific Posters
    • INDIGO Press Releases
    • INDIGO in the News
Print Friendly, PDF & Email

Live Cell Multiplex Assay Kits & Services

Product Family Product Number Product Description Technical Manual
LCMA LCM01 LCMA 1×96-wells Reagent Pack Technical Manual
LCM05 LCMA 5×96-wells Reagent Pack Technical Manual
LCM10 LCMA 10×96-wells Reagent Pack Technical Manual
  • Background
  • Services
  • Format & Performance

The Live Cell Multiplex (LCM) Assay provides an efficient fluorescence-based method of quantifying the relative number of live cells resident in treated wells of an assay plate. While the LCM Assay may be performed as a stand-alone assay, it has been specifically optimized to be run in multiplex with any of INDIGO’s 96-well, 2x48-well, or 3x32-well Nuclear Receptor Reporter Assay System products.

The LCM assay allows users to validate their primary Nuclear Receptor Assay data by determining if their test compound treatments exert mitogenic, cytostatic or cytotoxic activities on the reporter cells. The occurrence of such adverse non-specific effects will always undermine the accurate assessment of a test compound’s potency and/or efficacy as a modulator of nuclear receptor function.

When screening test compounds for antagonist activities it is particularly important to quantify changes in the relative number of live reporter cells at the assay endpoint. Test compounds that exert cytostatic, cytotoxic, or cytolytic activities invariably generate “false-positive” results in an antagonist screen. In such cases, the observed drop in luciferase activity will be incorrectly attributed to inhibition of the nuclear receptor by the test compound. In reality, however, the treatment compound has pushed the reporter cells into division arrest, apoptosis, necrosis, or lysis.

The LCM assay allows user’s to validate their primary Nuclear Receptor Assay data by determining if their test compound treatments exert mitogenic, cytostatic or cytotoxic activities on the reporter cells. The occurrence of such adverse non-specific effects will always undermine the accurate assessment of a test compound’s potency and/or efficacy as a modulator of nuclear receptor function.

When screening test compounds for antagonist activities it is particularly important to quantify changes in the relative number of live reporter cells at the assay endpoint. Test compounds that exert cytostatic, cytotoxic, or cytolytic activities invariably generate “false-positive” results in an antagonist screen. In such cases, the observed drop in luciferase activity will be incorrectly attributed to inhibition of the nuclear receptor by the test compound. In reality, however, the treatment compound has pushed the reporter cells into division arrest, apoptosis, necrosis, or lysis.

Format

Live Cell Multiplex Format The fluorescence-based LCM Assay and the luminescence-based INDIGO NR Assay are performed sequentially using the same assay wells. The text in blue corresponds to the LCM Assay portion of the multiplex protocol. Text in black corresponds to the standard protocol used for each of INDIGO’s 96-well format Nuclear Receptor Reporter Assays.

Performance

Live Cell Multiplex performance RFU = % Live Cells. The LCM Assay provides a direct correlation between % RFU and % Live Cells in an assay well.
INDIGO Biosciences - The right partner for all your discovery and toxicology needs.
Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Simply fill out this form and we'll be in touch!

Product Resources

  • Technical Manuals & Product Listing
    • Manuals & Listings: Other Kits
  • Assay Kit Platform & Formats
  • Request a Quote
  • Sample Study Report
  • Study Work Order Form
NRR - Nuclear Receptor Resource

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Home
  • Products
  • Request a Quote
  • FAQ

© 2020 INDIGO Biosciences, Inc. All Rights Reserved